PRME

Prime Medicine, Inc.

8.19 USD
+0.66 (+8.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Prime Medicine, Inc. stock is up 71.34% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 8 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 May 13:30 17 May, 2024 5.00 CALL 593 507
21 May 19:19 18 Oct, 2024 7.50 CALL 180 323

About Prime Medicine, Inc.

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

  • HC Wainwright & Co.
    Mon May 20, 07:57
    buy
    initial
  • Citigroup
    Thu May 16, 10:54
    buy
    upgrade
  • JP Morgan
    Mon May 13, 10:41
    buy
    confirm
  • Jefferies
    Tue May 7, 10:55
    buy
    initial
  • Wedbush
    Tue Apr 23, 13:13
    buy
    confirm
  • Chardan Capital
    Mon Apr 22, 07:48
    buy
    initial